摘要
卵巢交界性肿瘤(BOT)不同于良性肿瘤和癌,其主要见于年轻妇女,临床分期早,预后好,但是仍有少数患者疾病复发并死亡。大多数BOT患者通过手术可以治愈,但对于有浸润性种植的患者来说其临床预后差。BOT术后化疗的价值目前仍存在许多争议。文章将着重探讨BOT术后化疗的价值评估。
Epithelial borderline ovarian tumors （BOT） are distinctive from benign tumors and carcinoma. They occur in younger women, are present at an early stage, and have a favorable prognosis, but symptomatic re- currence and death may be found in some patients. Most BOT are cured with surgery; however BOT with invasive implants has a poor prognosis.Adjuvant treatment for BOT remains highly debatable. This article will evaluate the value of platinum-based adjuvant treatment for oatients with BOT.
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2015年第11期1001-1005,共5页
Chinese Journal of Practical Gynecology and Obstetrics
关键词
卵巢交界性上皮性肿瘤
辅助化疗
预后
epithelial borderline ovarian tumors
adjuvant chemotherapy
prognosis
